Polymers for the treatment of Alzheimer’s disease
Alzheimer’s disease (AD) is one of the most common diseases of the central nervous system in the middle-aged and elderly population. It is a neurodegenerative disorder, and its main clinical symptoms include the loss of established memories, a decline in learning capacity, and the buildup of β-amylo...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1512941/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582900862681088 |
|---|---|
| author | Yunfeng Zhu Haibin Xu Chaoyan Yu Wenting Jiang Xiaowen Hou Mingyue Ma Ji Wu |
| author_facet | Yunfeng Zhu Haibin Xu Chaoyan Yu Wenting Jiang Xiaowen Hou Mingyue Ma Ji Wu |
| author_sort | Yunfeng Zhu |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is one of the most common diseases of the central nervous system in the middle-aged and elderly population. It is a neurodegenerative disorder, and its main clinical symptoms include the loss of established memories, a decline in learning capacity, and the buildup of β-amyloid peptides. The disease is often accompanied by neurodegenerative changes and the formation of neurofibrillary tangles. However, the number of drugs available for the clinical treatment of AD remains limited. Currently, existing medications are not effective in completely curing the disease or stopping its progression. Due to their excellent biocompatibility and biodegradability, polymers have been widely used as drug delivery carriers in various fields including cancer therapy and wound healing. The use of polymers enables targeted drug delivery and prolonged release profiles. In recent years, researchers have made significant progress in utilizing polymers such as polyethylene glycol, poly (lactic-co-glycolic acid) (PLGA), and chitosan (CS) to deliver drugs and blood-brain barrier receptor ligands for the treatment of AD. Moreover, many polymers with inherent therapeutic properties have been developed, including the already marketed GV-971 as well as experimental polymers such as PLGA and CS oligosaccharide. This review summarizes the applications of polymers in AD treatment over the past few years and highlights their current limitations to help researchers better understand current advancements in polymer development and identify future research directions. |
| format | Article |
| id | doaj-art-57a4e9e2bfb84f2fb9f1d8877d5780a6 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-57a4e9e2bfb84f2fb9f1d8877d5780a62025-01-29T06:45:44ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011610.3389/fphar.2025.15129411512941Polymers for the treatment of Alzheimer’s diseaseYunfeng Zhu0Haibin Xu1Chaoyan Yu2Wenting Jiang3Xiaowen Hou4Mingyue Ma5Ji Wu6The Second Clinical Medical College, Shenyang Medical College, Shenyang, ChinaDepartment of Neurology, Juntendo University, Tokyo, JapanThe First Clinical Medical College, Shenyang Medical College, Shenyang, ChinaSchool of Public Health, Shenyang Medical College, Shenyang, ChinaSchool of Public Health, Shenyang Medical College, Shenyang, ChinaSchool of Public Health, Shenyang Medical College, Shenyang, ChinaSchool of Public Health, Shenyang Medical College, Shenyang, ChinaAlzheimer’s disease (AD) is one of the most common diseases of the central nervous system in the middle-aged and elderly population. It is a neurodegenerative disorder, and its main clinical symptoms include the loss of established memories, a decline in learning capacity, and the buildup of β-amyloid peptides. The disease is often accompanied by neurodegenerative changes and the formation of neurofibrillary tangles. However, the number of drugs available for the clinical treatment of AD remains limited. Currently, existing medications are not effective in completely curing the disease or stopping its progression. Due to their excellent biocompatibility and biodegradability, polymers have been widely used as drug delivery carriers in various fields including cancer therapy and wound healing. The use of polymers enables targeted drug delivery and prolonged release profiles. In recent years, researchers have made significant progress in utilizing polymers such as polyethylene glycol, poly (lactic-co-glycolic acid) (PLGA), and chitosan (CS) to deliver drugs and blood-brain barrier receptor ligands for the treatment of AD. Moreover, many polymers with inherent therapeutic properties have been developed, including the already marketed GV-971 as well as experimental polymers such as PLGA and CS oligosaccharide. This review summarizes the applications of polymers in AD treatment over the past few years and highlights their current limitations to help researchers better understand current advancements in polymer development and identify future research directions.https://www.frontiersin.org/articles/10.3389/fphar.2025.1512941/fullAlzheimer’s diseasepolymerdrug delivery systemspsychiatrynanoparticle |
| spellingShingle | Yunfeng Zhu Haibin Xu Chaoyan Yu Wenting Jiang Xiaowen Hou Mingyue Ma Ji Wu Polymers for the treatment of Alzheimer’s disease Frontiers in Pharmacology Alzheimer’s disease polymer drug delivery systems psychiatry nanoparticle |
| title | Polymers for the treatment of Alzheimer’s disease |
| title_full | Polymers for the treatment of Alzheimer’s disease |
| title_fullStr | Polymers for the treatment of Alzheimer’s disease |
| title_full_unstemmed | Polymers for the treatment of Alzheimer’s disease |
| title_short | Polymers for the treatment of Alzheimer’s disease |
| title_sort | polymers for the treatment of alzheimer s disease |
| topic | Alzheimer’s disease polymer drug delivery systems psychiatry nanoparticle |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1512941/full |
| work_keys_str_mv | AT yunfengzhu polymersforthetreatmentofalzheimersdisease AT haibinxu polymersforthetreatmentofalzheimersdisease AT chaoyanyu polymersforthetreatmentofalzheimersdisease AT wentingjiang polymersforthetreatmentofalzheimersdisease AT xiaowenhou polymersforthetreatmentofalzheimersdisease AT mingyuema polymersforthetreatmentofalzheimersdisease AT jiwu polymersforthetreatmentofalzheimersdisease |